References
- DeBaun MR, Frei-Jones M, Vichinsky E. Hemoglobinopathies. In: Kliegman RM, Behrman RE, Jenson HB, et al., Eds. Nelson Textbook of Pediatrics. 19th ed. Philadelphia, PA: Saunders Elsevier. 2011: chap 456
- Viprakasit V, Lee-Lee C, Chong QT, et al. Iron chelation therapy in the management of thalassemia: The Asian perspectives. Int J Hematl. 2009;90(4):435–445
- El-Beshlawy A, Kaddah N, Moustafa A, et al. Screening for β-thalassaemia carriers in Egypt: Significance of the osmotic fragility test. East Mediterr Health J. 2007;13(4):780–786
- Borgna-Pignatti C. Modern treatment of thalassaemia intermedia. Br J Haematol. 2007;138(3):291–304
- Fung EB. Nutritional deficiencies in patients with thalassemia. Ann N Y Acad Sci. 2010;1202:188–196
- Russo A, Schiliro G. Thalassemia major and malignancies. Am J Hematol. 1987;24(1):111–112
- Miniero R, Saracco P. Cancer in thalassemia and other hemoglobinopathies. Am J Hematol. 1988;27(1):74
- Alavi S, Safari A, Sadeghi E, Amiri S. Hematological malignancies complicating β-thalassemia syndromes: A single center experience. Blood Res. 2013;48(2):149–151
- Quattrin N, Mastrobouni A, Laudisio FL, et al. Hb Lepore and (haemo-) blastomata. Folia Haematol Int Mag Klin Morphol Blutforsch. 1976;103(6):915–919
- Zurlo MG, De Stefano P, Borgna-Pignatti C, et al. Survival and causes of death in thalassaemia major. Lancet. 1989;2(8653):27–30
- Karimi M, Giti R, Haghpanah S, et al. Malignancies in patients with β-thalassemia major and β-thalassemia intermedia: A multicenter study in Iran. Pediatr Blood Cancer. 2009;53(6):1064–1067
- Panich V, Na-Nakorn S, Piankijagum A. Hemoglobinopathies and G6PD deficiency in lymphoma. J Med Assoc Thailand. 1974;57:1–10
- Karimi M, Cohan N, Mousavizadeh K, et al. Adverse effects of hydroxyurea in β-thalassemia intermedia patients: 10 years’ experience. Pediatr Hematol Oncol. 2010;27(3):205–211
- Naithani R, Chandra J, Bhattacharjee J, et al. Peroxidative stress and antioxidant enzymes in children with β-thalassemia major. Pediatr Blood Cancer. 2006;46(7):780–785
- Toyokuni S. Role of iron in carcinogenesis: Cancer as a ferrotoxic disease. Cancer Sci. 2009;100(1):9–16
- Huang X. Does iron have a role in breast cancer? Lancet Oncol. 2008;9(8):803–807
- Kaur P, Basu S. Transfusion-transmitted infections: Existing and emerging pathogens. J Post-Grad Med. 2005;51(2):146–151
- Richardson DR. Potential of iron chelators as effective antiproliferative agents. Can J Physiol Pharmacol. 1997;75(10–11):1164–1180
- Jiao Y, Wilkinson J 4th, Di X, et al. Curcumin, a cancer chemopreventive and chemotherapeutic agent, is a biologically active iron chelator. Blood. 2009;113(2):462–469
- Joosten E, Meeuwissen J, Vandewinckele H, Hiele M. Iron status and colorectal cancer in symptomatic elderly patients. Am J Med. 2008;121(12):1072–1077
- Borgna-Pignatti C, Vergine G, Lombardo T, et al. Hepatocellular carcinoma in the thalassaemia syndromes. Br J Haematol. 2004;124(1):114–117